Assessment of antisperm antibodies in patients with hepatitis C virus infection: A controlled study

Rashad M. Mostafa¹, Nashaat M. Soliman², Nourhan E. Mohamed³, Hany M. Saad⁴

¹Department of Dermatology and Andrology, ²Department of Internal Medicine, Faculty of Medicine, Suez Canal University, ³Department of Dermatology, Al-Ismailia General Hospital, Ismailia, Egypt

ABSTRACT

Background: Antisperm antibody (ASA) is defined as an immunoglobulin with antibody activity against a sperm antigen that plays a role in fertility. It has been hypothesized that hepatitis C virus (HCV) infection of lymphocytes is the cause for the increased autoimmune phenomena and autoantibody production reported in association with HCV. The development of ASA has been previously reported in cases with human papilloma virus (HPV), where infertile males with HPV in semen showed higher ASA percentages compared with infertile males with no HPV in semen.

Aim: To investigate the influence of HCV infection on the development of ASAs in diagnosed HCV male patients.

Patients and Methods: The study included two groups: group one included 25 patients who were infected with HCV, and group two included 25 healthy controls. Semen analyses by CASA were performed and serum and semen samples were taken for all patients to detect ASA by enzyme-linked immunosorbent assay.

Results: In the patient group, 28% were positive for ASA in semen versus 4% in the control group with a statistically significant difference between the two groups (P=0.049). ASA levels in serum were positive in 36% of patients versus 12% in the control group with a statistically significant difference between the two groups (P=0.047). There were significant negative correlations between progressive motility, agglutination, and the level of patient’s ASA in both serum (r=‒0.635, P<0.001, r=‒0.749, P<0.001, respectively) and semen (r=‒0.764, P=0.001; r=‒1, P<0.001, respectively).

Conclusion: The coincidence of ASA in males with hepatitis C infection diseases was significantly higher than healthy controls.

Key Words: Antisperm antibody, hepatitis C virus, infertility.

Received: 18 December 2021, Accepted: 20 December 2021

Corresponding Author: Hany M. Saad, Department of Dermatology and Andrology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt, Tel.: 00203203112, E-mail: h_saad20@hotmail.com

ISSN: 2090-6048, 2022

INTRODUCTION

Since not every antibody that binds to the sperm surface influences sperm function, antisperm antibodies (ASA) are defined as immunoglobulins with antibody activity against a sperm antigen that plays a role in fertility(1).

ASAs are found in the serum and seminal plasma and are bound directly to spermatozoa. ASAs frequently impair sperm motility(2).

The association between viral infections and the development of ASAs has been previously reported in cases with human papilloma virus (HPV), where infertile male patients with HPV in semen showed higher ASA percentages than infertile males with no HPV in semen(3).

The hepatitis C virus (HCV) is a viral infection that causes both hepatic and extrahepatic disease. HCV infection is a major and common public health issue. It has been proposed that HCV infection of lymphocytes is the cause of the increased autoimmune phenomena and autoantibody production associated with HCV(4). HCV-RNA was found in the semen of HCV patients, albeit in low concentrations and not in all HCV-positive patients(5). It was found that HCV infection was associated with impaired sperm motility(6).

The same effect was observed in cases with positive ASAs in semen(7). On the basis of preceding data, we can conclude that HCV may influence the development of ASAs and impair sperm motility. So we aimed to assess the effect of HCV infection on the development of seminal androgen serum ASAs and their effect on motility in HCV males.

PATIENTS AND METHODS

This was a case-control, descriptive study. The study was carried out on fertile men attending the hepatitis C center in Tropical Hospital and Andrology Outpatient Clinic Suez Canal University Hospital. The study included...
two groups; group 1 (the patient group) included 25 HCV-positive fertile males, with elevated liver enzymes of more than 6 months and positive PCR test for HCV. Group 2 (control group) included 25 HCV-negative fertile males. After receiving the Institutional Review Board approval, the study was carried out in accordance with the Helsinki Declaration guidelines (1964). All participants provided written informed consent. Exclusion criteria included; males above 60 years old, patients who had azoospermia or severe oligozoospermia (<5 x 10^6 sperm/ml), and patients who had clinical evidence of varicocele, history of testicular surgery, testicular torsion, trauma, epididymo-orchitis and cryptorchidism. Males in the two groups were subjected to detailed history taking and clinical examination. Laboratory investigations for all participants included the following: semen analysis and the semen was collected by masturbation after 4–5 days of sexual abstinence and the collected semen was allowed to liquefy at 37°C. Analyses of samples were performed according to WHO 2010 guidelines [8]. Seminal plasma IgG ASA and serum IgG ASA were measured by enzyme-linked immunosorbent assay (BIOSERV Kits, Germany). In brief, ASA levels in serum and semen were quantified using a BIOSERV Kits, Germany. The extinction was measured at a wavelength of 450nm with a microplate reader (Bio-Radi Laboratories, Hercules, California, USA).

The sample size was calculated using the following formula [9]:

\[
n = \frac{2 \left( \frac{Z_{\alpha/2} + Z_{\beta}}{\mu_1 - \mu_2} \right)^2 \sigma^2}{\left( \mu_1 - \mu_2 \right)^2}
\]

Where \(n\) = sample size, \(Z_{\alpha/2}=1.96\) (the critical value that divides the central 95% of the \(Z\) distribution from the 5% in the tail.), \(Z_{\beta}=0.84\) (the critical value that separates the lower 20% of the \(Z\) distribution from the upper 80%), \(\sigma\) = the estimate of the standard deviation of SperMar IgG test = 13.67%, \(\mu_1\) = mean in the study group = 8.83%, and \(\mu_2\) = mean in the control group = 20.33% [10].

So, the sample size will be 25 cases per group, giving a total sample size of 50 cases.

Statistical analysis

Data were fed into the computer and analyzed using IBM SPSS software package, version 20.0 (IBM Corp., Armonk, New York, USA). Qualitative data were described using number and percent. The Kolmogorov–Smirnov test was used to verify the normality of distribution. Quantitative data were described using range (minimum and maximum), mean, SD, and median. Significance of the obtained results was judged at the 5% level. \(\chi^2\) test was used to study comparison and association between two qualitative variables. Student’s \(t\) test was used for comparison between two groups having quantitative variables with normal distribution (for parametric data).

RESULTS

This case–control study included two groups: the first group included 25 HCV-positive fertile males and the second group included 25 HCV-negative fertile males. Each patient underwent semen analysis, seminal IgG ASA, and serum IgG ASA done by enzyme-linked immunosorbent assay.

The mean age in HCV patients was 36 years and in control it was 34 years. The percentage of smokers in the patient and control groups was comparable (48.0 vs. 44%, respectively). All the participants were married. None of the controls suffered from any chronic illness; meanwhile, all of the 25 patients had HCV infection (Table 1, Fig.1).

| Table 1: Demographic characteristics of the study groups |
|----------------------------------------------------------|
|                                                          |
| Age                                                      |
| Mean ±SD                                                 |
| 36.04±8.55                                               |
| Minimum–maximum                                          |
| 30.0–57.0                                                |
| Smoking [n (%)]                                          |
| Yes                                                      |
| 12(48)                                                   |
| No                                                       |
| 13(52)                                                   |
| Marital status [n (%)]                                   |
| Married                                                  |
| 25(100)                                                  |
| Single                                                   |
| 0                                                        |
| Chronic illness [n (%)]                                  |
| No                                                       |
| 0                                                        |
| Yes                                                      |
| 25(100)                                                  |

2
There was no significant difference in the mean of total sperm motility between the two groups ($P>0.05$). Meanwhile, progressive motility showed a statistically significant decline by about 8% in HCV patients compared with controls ($P=0.040$). Pyospermia was absent in the majority of HCV patients and controls, with no statistically difference between the two groups ($P>0.05$). Neither HCV patients nor controls had hemospermia (Table 2). There was a statistically significant increase in sperm agglutination of patients by about 24% compared with controls ($P=0.049$) (Table 2). Nine (36.0%) patients with HCV had positive serum ASA against only three (12%) controls with a statistically significant difference between the two groups ($P=0.047$). A similar finding was in semen as seven (28%) HCV patients had positive semen ASA versus only one (4.0%) case in the control group with a statistically significance difference between the two groups ($P=0.047$) (Table 3).

**Table 2:** Semen analysis parameters of the study groups

|                  | HCV (N=25) | Control (N=25) | $P$  |
|------------------|------------|----------------|------|
| Volume (ml)      | 1.50–8.0   | 1.50–9.0       | 0.906|
| Minimum–maximum  |            |                |      |
| Mean ±SD         | 3.58±1.59  | 3.62±1.77      |      |
| Viscosity[n%]    |            |                |      |
### Antisperm Antibodies in Hepatitis C Patients

**Table 3:** Comparison between the two studied groups according to antisperm antibody

|                | HCV (N=25) [n (%)] | Control (N=25) [n (%)] | P     |
|----------------|--------------------|------------------------|-------|
| ASA in serum   |                    |                        |       |
| Positive       | 9 (36.0)           | 3 (12.0)               | 0.047*|
| Negative       | 16 (64.0)          | 22 (88.0)              |       |
| ASA in semen   |                    |                        |       |
| Positive       | 7 (28.0)           | 1 (4.0)                |       |
| Negative       | 18 (72.0)          | 24 (96.0)              | 0.049*|

ASA, antisperm antibody; HCV, hepatitis C virus; P: P value for comparing between the studied groups.

*Statistically significant at P value less than or equal to 0.05.

In the patient group, there was a statistically significant relationship between agglutination and ASA in semen (P≤0.001) as all the seven cases, which showed agglutination in semen, were positive for ASA in semen as well all the 18 cases, which showed no agglutination, were negative for ASA in semen (Table 4).

There were statistically significant negative correlations between progressive motility, agglutination, and the level of patient’s ASA in both serum (r=-0.635, P<0.001; r=-0.749, P<0.001, respectively) and semen (r=-0.746, P=0.001; r=-1, P<0.001, respectively) (Table 5).
### Table 4: Comparison between agglutination and antisperm antibody in semen in the hepatitis C virus group (N=25)

| Agglutination | ASA in semen [n (%)] |
|---------------|----------------------|
|               | +ve (N=7)            | -ve (N=18) |
| No            | 0                    | 18 (100.0) |
| Yes           | 7 (100.0)            | 0          |

ASA, antisperm antibody; *P* value for comparing between the studied groups.

*Statistically significant at *P* value less than or equal to 0.05.

### Table 5: Correlation between antisperm antibody in serum, antisperm antibody in semen, and different parameters in hepatitis C virus group (N=25)

| ASA in serum | ASA in semen |
|--------------|-------------|
| *r*          | *P*         | *r*          | *P*         |
| Progressive motility | -0.635*     | 0.001*       | -0.746*     | <0.001*    |
| Agglutination | 0.749*      | <0.001*      | -1.000*     | <0.001*    |

ASA, antisperm antibody; rs, Spearman coefficient.

*Statistically significant at *P* value less than or equal to 0.05.

### DISCUSSION

This study assessed the ASA in serum and semen of men who were infected with HCV. The current study found that patients with HCV had statistically significantly higher semen and serum ASA than controls (*p*=0.047, respectively).

Bourlet et al.\[^5\]\ demonstrated that in HCV patients, the detection of HCV-RNA in the sperm was reported, albeit at low concentrations and not in all HCV-positive patients. That comes in agreement with Shiraishi et al.\[^11\]\ as they tested ASA in the sera of 70 males with systemic autoimmune diseases and 80 healthy controls and found that the incidence of ASA was significantly higher in the patient group, as five patients were with positive indirect-immunobead test; meanwhile, no positives existed in 80 healthy males. One of them had chronic hepatitis and possessed all three classes of IgA, IgG, and IgM.

Viral infections, including HCV infection, were thought to be a potential cause of autoimmune diseases. Therefore, Shiraishi et al.\[^11\]\ hypothesized that the state of chronic HCV infection may have induced ASA as an autoimmune disorder.

Hussein et al.\[^10\]\ conducted a study on 30 HCV-infected individuals and 30 healthy controls and found that HCV-infected patients had higher IgG seminal levels than healthy controls. In addition, they detected a significant decrease in sperm motility in HCV patients compared with controls. In our study, though we did not find a significant difference in total sperm motility between the two groups (*P*=0.256), there was a significantly lower progressive motility in the patient group than controls (*P*=0.04).

This can be elucidated by the work of Zini et al.\[^7\]\, who reported that HCV could contribute to the impaired sperm motility seen in HCV patients through promoting the development of ASAs which interfere with sperm motility. In addition, Levy et al.\[^12\]\ hypothesized that HCV-RNA in the seminal plasma may interfere with sperm motility through passive adsorption into the cell membrane.

In the current study, sperm concentration in the patient group was significantly lower than controls (*P*<0.001). This agrees with Durazzo et al.\[^13\]\, who reported a difference in sperm concentration between controls and HCV-infected patients. In our study, though we did not find a significant difference in total sperm motility between the two groups (*P*=0.256), there was a significantly lower progressive motility in the patient group than controls (*P*=0.04).
patients, implying that HCV may have a negative impact on spermatogenesis. In another study, Hofer et al.\textsuperscript{[14]} also reported low sperm concentration in most or all of their chronic HCV patients compared with fertile controls.

Moretti et al.\textsuperscript{[15]}, on the other hand, conducted a study on 34 HCV-infected patients and found that some patients had normal sperm concentration. This is may be attributed to the evaluation of semen samples, according to the WHO 1999 guidelines\textsuperscript{[16]}, whereas our study used the WHO 2010 guidelines\textsuperscript{[8]}.

The small sample size and lack of randomization were significant limitations of this study. We, however, used a control group and an equation for sample size calculation to reinforce the study.

CONCLUSION

The incidence of ASA in males with hepatitis C infection diseases was significantly higher than in the healthy controls. These ASAs are directly related to and are negatively correlated with sperm progressive motility and agglutination.

CONFLICT OF INTEREST

There are no conflicts of interest.

REFERENCES

1. MahmoudAM, TuyttensCL, ComhaireFH. Clinical and biological aspects of male immune infertility: a case-controlled study of 86 cases. Andrologia 1996; 28:191–196.

2. WalshTJ, TurekPJ. Immunologic infertility. In: LipshultzL, HowardsS and NiederbergerC. 4th edition. infertility in the male. Cambridge: Cambridge University Press; 2009. 277–294.

3. GarollaA, PizzoliD, BertoldoA, De ToniL, BarzonL, ForestaC. Association, prevalence, and clearance of human papillomavirus and antisperm antibodies in infected semen samples from infertile patients. Fertil Steril 2013; 99:125–131.

4. AgnelloV, De RosaF. Extrahepatic disease manifestations of HCV infection: some current issues. J Hepatol 2004; 40:341–352.

5. BourletT, LevyR, MaertensA, TardyJC, GrattardF, CordonierH, PozzettoB. Detection and characterization of hepatitis C virus RNA in seminal plasma and spermatozoa fractions of semen from patients attempting medically assisted conception. J Clin Microbiol 2002; 40:3252–3255.

6. LorussoF, PalmisanoM, ChironnaM, VacciaM, MasciandaroP, BassiE, et al. Impact of chronic viral diseases on semen parameters. Andrologia 2010; 42:121–126.

7. ZiniA, PhillipsS, LefebvreJ, BaazeemA, BissonnetteF, KadochJJ, GabrielMS. Anti-sperm antibodies are not associated with sperm DNA damage: a prospective study of infertile men. J Reprod Immunol 2010; 85:205–208.

8. World Health Organization (WHO), WHO laboratory manual for the examination and processing of human semen. 5th ed. Geneva: World Health Organization; 2010.

9. DawsonB, TrappRG. Basic and clinical biostatistics. (4th E). New York, USA: LANGE Basic Science; 2004.

10. HusseinTM, ElneilyD, EidAA, Abou-ElKhierH. Assessment of antisperm antibodies in a sample of Egyptian patients with hepatitis C virus infection. Andrologia 2017; 49:e12664.

11. ShiraishiY, ShibaharaH, KoriyamaM, HiranoY, OkazakiH, MinotaS, SuzukiM. Incidence of antisperm antibodies in males with systemic autoimmune diseases. Am J Reprod Immunol 2009; 61:183–189.

12. LevyR, BourletT, MaertensA, SalleB, LorangeJ, LaurentJL, et al. Pregnancy after safe IVF with hepatitis C virus RNA-positive sperm: case report. Hum Reprod 2002; 17:2650–2653.

13. DurazzoM, PremoliA, Di BisceglieC, BertagnaA, FagàE, BirolìG, et al. Alterations of seminal and hormonal parameters: an extrahepatic manifestation of HCV infection?. World J Gastroenterol 2006; 12:3073.

14. HoferH, DonnererJ, SatorK, StauferK, ScherzerTM, DejacoC, et al. Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy. J Hepatol 2010; 52:812–816.

15. MorettiE, FedericoMG, GianneriniV, CollodeGI. Sperm ultrastructure and meiotic segregation in a group of patients with chronic hepatitis B and C. Andrologia 2008; 40:286–291.

16. World Health Organization (WHO), WHO laboratory manual for the examination of human semen and sperm-cervical mucus interaction. 4th ed. Cambridge: Cambridge University Press; 1999.